By disrupting the pathological cycle of oxidative hypoxia while maintaining physiological HIF-1α regulation, ACF-2 has the potential to serve as the basis for future therapeutic approaches aimed at halting or even reversing pulmonary fibrosis. Here, HIF1A is linked to pulmonary fibrosis.